Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) announced Tuesday that its antibody cocktail drug showed positive effects in non-hospitalized COVID-19 patients. What Happened: Analysis of data from a 275 person study indicates that the REGN-COV2 drug cocktail led to reduced viral load and time to alleviate symptoms of COVID-19, Regeneron said in a statement.

Regeneron Says COVID-19 Antibody Cocktail Helped Non-Hospitalized Patients Heal Faster In Early Trials

Experts say more data is needed before drawing any conclusions.

New Drug Might Speed Up Covid-19 Recovery, Pharma Company Reports

Regeneron Pharmaceutical posted positive data from its Covid-19 treatment trials; an announcement that came after the close of Tuesday's regular session but could spark REGN stock.
The post Regeneron Pharmaceutical Posts Positive Initial Data On Its Covid-19 Treatment appeared first on Investor's Business Daily.

Regeneron Pharmaceutical Posts Positive Initial Data On Its Covid-19 Treatment

Shares of Regeneron Pharmaceuticals Inc. were halted in late trading Tuesday after the drug maker said its trial antiviral drug cocktail reduced the coronavirus load and the time needed to ease symptoms in non-hospitalized patients with COVID-19.

Regeneron says that trial coronavirus drug cocktail cut virus load, aided patient recovery

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues investigating whether certain directors and officers of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:...

Scott+Scott Attorneys at Law LLP Continues Investigating Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty - REGN

Alexion Pharma

Amgen

Biogen

Gilead Sciences

Vertex Pharmaceuticals

The short interest data are out for September 15, the most recent settlement date.

Biotech Short Sellers Hike Their Bets

Check Point Software Technologies

Grand Canyon Education

MarketAxess Holdings

New Historical Data Screen identifies good stocks

4 Stocks With Strong Earnings Growth Over the Past 5 Years

Abbott Labs

BioNTech SE

Pfizer

These companies may be near-term and long-term winners -- thanks to coronavirus work and solid product portfolios.

3 Safe Coronavirus Stocks to Buy Ahead of a Market Crash

AstraZeneca

Coronavirus concerns seem to be lifting as the markets churn higher, but is this a carrot-or-the-stick question?

This Week in Coronavirus News

GlaxoSmithKline

Don't forget these two stocks when preparing your portfolio for the next market crash.

2 COVID-19 Antibody Stocks to Buy Right Now

Genmab - ADR

Innoviva

Mersana Therapeutics

Novavax

Bio-Techne

Vanda Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Biotech Stocks for Q4 2020

Regeneron Pharmaceuticals, Inc. (REGN) Management at Cantor Fitzgerald Virtual Global Healthcare Conference Transcript

BERKELEY, Calif.--(BUSINESS WIRE)--Regeneron and University of Lausanne Publish Newomics M3 Emitters in Peer-reviewed Scientific Journals.

Regeneron and University of Lausanne Publish Newomics M3 Emitters

Regeneron's (REGN) investigational anti-viral antibody cocktail, REGN-COV2, has been selected for evaluation in the RECOVERY study.

Regeneron's Cocktail for Coronavirus Selected for RECOVERY Study

If this biotech company's antibody treatment works, it could take take over not one market -- but two.

Could This COVID-19 Drug Developer's Stock Make You Filthy Rich?

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

TARRYTOWN, N.Y. and OXFORD, England, Sept.

RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK

The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Hike Their Bets in Major Biotechs

Takeda Pharmaceutical

vTv Therapeutics

Zoetis

A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.

5 of the Best Pharmaceutical Stocks to Buy Right Now

Royalty Pharma

Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi's 15th Annual BioPharma Virtual Conference (Transcript)

Incyte

Vertex, Inc.

Not all biotechs are created equal.  Strong balance sheets  can separate the weak from the strong.

Biotechs With Strong Balance Sheets

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc.

Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

News for Regeneron Pharmaceuticals Stock (REGN)